期刊文献+

大肠癌组织HLA-I基因蛋白的表达及意义 被引量:2

The protein expression of HLA-I on colorectal carcinoma
下载PDF
导出
摘要 目的探讨大肠癌组织HLA-I蛋白的表达。方法 41例大肠癌组织中,14例是高分化腺癌,17例是中分化腺癌,10例是低分化腺癌。用抗HIA-I抗原的单克隆抗体做免疫组织化学分析。结果阳性组织中细胞膜和细胞浆着色。HLA-I在大肠组织中阳性表达率为36.59%,在正常组织中阳性表达率为80%,P<0.05。在不同组织学分级中,HLA-I表达有统计学差异,P<0.05。在淋巴结转移与否的癌组织中HLA-I表达无统计学差异,P>0.05。结论大肠癌组织中HLA-I基因蛋白表达下降, 不同组织学分级表达有统计学差异,淋巴结转移与否无统计学差异。 Objective To measure the protein expression of human leukocyte antigen class I on colorectal carcinoma. Methods Among 41 colorectal carcinoma cases, 14 cases were well differentiated adenocarcinoma, 17 cases were moderate differentiated ones and 10 were low differentiated ones. HLA-I antigens were detected by immunohistochemistry using monoclonal antibody against HLA-I antigens. Results The expression of HLA-I on the positive cell membrane and cytoplasmic expression were observed. The positive rate of HLA-I was 36.59% in colorectal carcinoma.Which was 80% in normal tissues.There was a significant difference between two groups ( P 〈 0.05) .The expression of HLA-I in cancer tissues was correlated statistically with the degree of differentiation ( P 〈 0.05) .The expression in cases with lymph node metastasis was not correlated statistically with those without lymph node metastasis ( P 〉 0.05). Conclusion The expression of HLA-I is lower in colorectal carcinoma than that in normal tissues and positively correlated with histological grade of cancer, but not with lymph node metastasis.
出处 《河北医药》 CAS 2006年第1期7-8,共2页 Hebei Medical Journal
基金 河北省科技厅科技公关项目课题 项目编号(042761517)
关键词 大肠癌 HLA-I 免疫组化 colorectal carcinoma HLA-I immunohistochemistry
  • 相关文献

参考文献8

二级参考文献50

  • 1张亚厉 张振书 杨希山主编.大肠癌的基础与临床:第1版[M].上海:上海科学技术出版社,1999.164.
  • 2Levine A J, Perry ME, Chang A, et al. The 1993 walter Hubert lecture: the role of th 1353 tumor suppressor gene in tumorigenesis. Br J Cancer, 1994,69:409.
  • 3Monica H, David S, Bert V, et al. p53 mutation in human cancer. Science,1991,293:49.
  • 4Baker SJ, Fearon Er, Nigro MJ, et al. Chromsome 17 deletions and p53 gene mutations in colorectal carciranas. Science, 1989,244: 217.
  • 5Carson DA, Lois A. Cancer progression and p53. lancet, 1995,346:1009.
  • 6Baker SJ, Presinger AC, Jessup JM, et al. p53 gene nmtations occut in combination with 17p allelie deletions as late event in colorectal tumorigenesis.Cancer Rgs, 1990,50:7717.
  • 7Gob HS, Chan CS, Khine K, et al. p53 and behaviour of colorectal cancer Lancet, 1994,344:233.
  • 8LI J, Yen C, Liaw D, et al. Pten, A putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Scinece, 1997,295 : 1943.
  • 9Gantley LC,Neey BG.A new insight into tumor mppress,PTEN suppresses tumor for marion by restraining the phosphatidylinositide 3 kinase/AKT pathway. Proc Nail Acad Sci, 1999,90:4240.
  • 10Postel A, Berberich SJ, Flint SJ, et al. human c-myc transcription factor Puf identified as nm23-H2 mucleoside diphosphate kinase, a candidate suppressor of tumour metastasis.Science, 1993,261:478-480.

共引文献47

同被引文献8

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部